CYFRA 21-1 in the follow-up of patients with malignant pleural mesothelioma

被引:0
作者
Berzinec, P [1 ]
Zuffova, H [1 ]
机构
[1] Nitra Reg Hosp, Inst TB & Resp Dis, Nitra, Slovakia
来源
LUNG CANCER: CURRENT TOPICS | 2001年
关键词
malignant mesothelioma; CYFRA; 21-1; follow-up;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate serum tumour marker CYFRA 21-1 as a possible tool for follow-up of patients with malignant pleural mesothelioma (MPM). Methods: CYFRA 21-1 was repeatedly measured in 14 patients with MPM. ECLIA kits (Roche,formerly Boehringer Mannheim) were used for measurements. Randblock analysis of variance was used for statistical evaluation. Results: Elevated levels of CYFRA 21-1 (over 3.33 ng/ml) were found by the baseline, after 3, and after 6 months from baseline in 8 (57%), 9 (64%), and 10 (71%) patients respectively. CYFRA 21-1 levels changed significantly, the mean level increased from 14.46 (SD 22.77) to 34.23 (SD 52.14) ng/ml after 6 months (p <0.05). Changes of CYFRA 21-1 levels were consistent with the course of the disease. Conclusion: CYFRA 21-1 may be used as a marker for follow-up of patients with MPM.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 19 条
[1]  
BAAS P, 1996, LUNG CANCER, V15, P267
[2]  
BERGHMANS T, 1999, P AN M AM SOC CLIN, V18, P1858
[3]  
Berzinec P, 1996, NEOPLASMA, V43, P159
[4]  
BERZINEC P, 2000, P AN M AM SOC CLIN, V19, P665
[5]  
BISCHOFF HG, 1998, P AN M AM SOC CLIN, V17, P464
[6]  
BOZNER A, 1991, CYTOLOGY
[7]   Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study [J].
Byrne, MJ ;
Davidson, JA ;
Musk, AW ;
Dewar, J ;
van Hazel, G ;
Buck, M ;
de Klerk, NH ;
Robinson, BWS .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :25-30
[8]   CYFRA 21-1 enzyme-linked immunosorbent assay - Evaluation as a tumor marker in non-small cell lung cancer [J].
Lai, RS ;
Hsu, HK ;
Lu, JY ;
Ger, LP ;
Lai, NS .
CHEST, 1996, 109 (04) :995-1000
[9]  
Maass JD, 2000, ANTICANCER RES, V20, P2241
[10]  
Marukawa M, 1998, ACTA MED OKAYAMA, V52, P119